Stockscreener 앱 받기
2.14
2.88%
0.06
시간 외 거래:
2.14
전일 마감가:
$2.08
열려 있는:
$2.12
하루 거래량:
97,817
Relative Volume:
0.74
시가총액:
$214.88M
수익:
-
순이익/손실:
$-60.14M
주가수익비율:
-3.0162
EPS:
-0.7095
순현금흐름:
$-68.17M
1주 성능:
+0.94%
1개월 성능:
+3.38%
6개월 성능:
-20.45%
1년 성능:
-37.79%
1일 변동 폭
$2.07
$2.19
1주일 범위
$2.07
$2.50
52주 변동 폭
$1.4299
$3.98
Ac Immune Sa Stock (ACIU) Company Profile
ACIU을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
2.14 | 218.30M | 0 | -60.14M | -68.17M | -0.7095 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-31 | 개시 | BTIG Research | Buy |
| 2019-02-01 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-01-04 | 개시 | UBS | Buy |
| 2018-04-05 | 개시 | H.C. Wainwright | Buy |
| 2018-03-23 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2016-10-18 | 개시 | Credit Suisse | Outperform |
| 2016-10-18 | 개시 | Jefferies | Buy |
| 2016-10-18 | 개시 | Leerink Partners | Outperform |
모두보기
Ac Immune Sa 주식(ACIU)의 최신 뉴스
Backtesting results for AC Immune SA trading strategiesFree Community Entry Consensus Trade Ideas - Newser
Visual analytics tools that track AC Immune SA performanceShort-Term AI-Based Stock Price Forecast - Newser
Using AI based signals to follow AC Immune SAFree Short Term Buy Zone Stock Alerts - Newser
How to integrate AC Immune SA into portfolio analysis toolsDaily Breakout List with Smart Filters - Newser
Can machine learning forecast AC Immune SA recoveryFree High Accuracy Alerts for ROI Traders - Newser
What makes AC Immune SA stock price move sharplyForecasting Stock Moves with AI Insights - Newser
Can AC Immune SA expand its profit marginsSmart Beta Portfolio Candidates - sisaissue.com
Ranking AC Immune SA among high performing stocks via toolsFast Return Equity Forecast With Logic - Newser
Identifying reversal signals in AC Immune SADaily Stock Watch Summary with Key Insights - Newser
Q3 Earnings Forecast for AC Immune Issued By Leerink Partnrs - Defense World
AC Immune Reports Q2 2025 Financial Progress - TipRanks
Visualizing AC Immune SA stock with heatmapsFree Weekly Growth Stock Entry Point Alerts - Newser
Using data models to predict AC Immune SA stock movementCapital Growth Summary Over Five Years - Newser
Analyzing drawdowns of AC Immune SA with statistical toolsFree Weekly Stock Watch With Growth Focus - Newser
Chart based exit strategy for AC Immune SAImmediate Entry Point Prediction Strategy - Newser
Using R and stats models for AC Immune SA forecastingStock Market Watch with Smart Filters - Newser
Is AC Immune SA stock poised for growthWeekly Hot Stocks Based on Volume Flow - Newser
AC Immune SA: Promising Pipeline and Strong Financial Position Justify Buy Rating - TipRanks
Will AC Immune SA stock split in the near futureFree Low Risk Swing Trade Opportunity List - Newser
New Strong Sell Stocks for August 6th - Yahoo Finance
AC Immune: Q2 Earnings Snapshot - New Haven Register
AC Immune reports Q2 EPS (CHF 0.21) vs. (CHF 0.23) last year - TipRanks
AC Immune SA reports results for the quarter ended June 30Earnings Summary - TradingView
AC Immune SA Reports Increased Losses in Mid-2025 Financial Results - TipRanks
AC Immune SA Reports Q2 2025 Financial Results and Advancements in Neurodegenerative Disease Therapies - Quiver Quantitative
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewswire
AC Immune Reports Breakthrough: 20-Fold Antibody Increase in Parkinson's Treatment, Plus $157M Cash Runway - Stock Titan
When is the best time to exit AC Immune SATrend Reversal Watch with Entry Signals - Newser
Can momentum traders help lift AC Immune SASmart Risk Strategy with Entry Optimization - Newser
Ac Immune Sa (ACIU) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):